Clinical Study Results
Research Sponsor: AstraZeneca
Drugs Studied: Olaparib, ceralasertib, and adavosertib
Study Purpose: This study was designed to understand how
olaparib, ceralasertib, and adavosertib work in
participants with metastatic triple negative
breast cancer
Protocol Number: D5336C00001
Thank you
Thank you to the participants who took part in the clinical study for the study drugs olaparib,
ceralasertib, and adavosertib.
All of the participants helped researchers learn more about olaparib, ceralasertib, and adavosertib
to help people with triple negative breast cancer that has spread to other parts of the body or
surrounding breast tissue.
AstraZeneca sponsored this study and believes it is important to share the results of the study with
you and the public. An independent non-profit organization called CISCRP helped prepare this
summary of the study results for you. We hope it helps you understand and feel proud of your
important role in medical research.
If you participated in the study and have questions about the results, please speak with the study
doctor or staff at your study site.
1